Free for members and Non-Members

This activity is supported by independent educational grants from Incyte Corporation, Sanofi and Regeneron Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pfizer Inc., and Boehringer Ingelheim Pharmaceuticals Inc.

Course Description

Multiple skin conditions — including psoriasis, atopic dermatitis, and alopecia areata — are mediated by complex immunological pathways that drive disease onset and progression. Recent years have seen the introduction of novel targeted therapies inhibit cytokines that play key roles in these pathways, and many more related therapies are in development. Targeted immune-modulating therapies offer patients with moderate to severe disease additional opportunities to achieve and maintain disease control. However, the rapidly growing therapeutic armamentarium presents challenges for managed care professionals seeking to develop and implement evidence-based, patient-centered policies to ensure that the right patient has access to the right therapy at the right time. During Specialty Connect, experts will focus on managed care considerations for managing immune-mediated skin conditions. Topics will include the future pipeline, considerations for treatment selection, and formulary and financial risk management strategies.  

Specialty Connect is a strategic, forward-thinking pre-conference program designed to focus on topics important to those involved with specialty management. The program is designed for and with industry leaders, experts, and managed care professionals operating in this fast-growing sector and will provide opportunities to both learn and network with those interested in specialty management.